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ABSTRACT – Introduction - With the advent of long-lasting local anesthetics, local and 
regional anesthesia gained considerable impetus and the use of these techniques has 
become increasingly widespread. New block techniques have been described and regional 
anesthesia is frequently associated with general anesthesia to provide postoperative 
analgesia. In contrast, large doses of local anesthetics are required with the risk of accidents 
due to inadvertent intravascular injection, which is a severe complication without a specific 
treatment until a few years ago. In 1998, the use of lipid emulsions was proposed in animals. 
Since 2006, many studies have demonstrated an interest in these solutions in cases of local 
anesthetic-induced toxicity with a decrease in morbidity and mortality. The aim of this review 
article was to research the methodology, reviewing mechanisms, interests, limitations and 
currently recommended treatment. Method - Some historical references on local anesthetics, 
articles published during the last 30 years in journals indexed in Medline and in two 
textbooks were reviewed. Articles on local anesthetic toxicity, lipid emulsion therapy, review 
articles on the topic and treatment adopted in diverse services and countries were selected, 
producing a summary. Conclusions - It is no longer necessary to show the effectiveness and 
interest in lipid emulsion therapy for local anesthetic toxicity. Various specialty societies have 
already published their guidelines and advice about stocking these products in any setting 
in which local and regional anesthetic techniques are practiced.
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RESUMO – Introdução - Com o advento dos anestésicos locais de longa duração, a anestesia 
locorregional ganhou grande impulso sendo cada vez mais utilizada. Novas técnicas de 
bloqueios foram descritas e a técnica é frequentemente associada à anestesia geral com 
o objetivo de proporcionar analgesia pós-operatória. A contra-partida é a necessidade da 
utilização de grandes doses com risco de acidentes por injeção intravascular inadvertida; 
trata-se de complicação grave sem tratamento específico até há alguns anos. Em 1998 foi 
proposta a utilização de emulsões lipídicas em animais e a partir de 2006 vários trabalhos 
demonstraram o interesse dessas soluções nos casos de intoxicações por anestésicos locais 
com diminuição da morbi-mortalidade. O objetivo desta revisão foi fazer um levantamento 
da metodologia, revisando os mecanismos, interesses, limites e as condutas preconizadas 
atualmente. Método - Foram revistas algumas referências históricas sobre anestésicos locais, 
artigos publicados nos últimos 30 anos em revistas indexadas no Medline e em dois livros-
texto. Foram selecionados os artigos que tratavam da intoxicação por anestésicos locais, da 
terapia com emulsões lipídicas, os de revisão sobre o assunto e as condutas adotadas em 
diversos serviços e países, sendo realizada uma síntese. Conclusões - A eficiência e interesse 
da terapia com emulsões lipídicas nas intoxicações por anestésicos locais não é mais a 
demonstrar; várias sociedades da especialidade já publicaram suas diretrizes e aconselham 
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INTRODUCTION
Local anesthetic toxicity has been recognized long before the introduction of cocaine in clinical practice. In 1868, a Peruvian physician named Moreno y Maiz in pursuit a doctorate degree in 
Paris described the first signs and symptoms of cocaine toxicity in an animal 
study22. This occurred 16 years before cocaine was used for the first time by 
Karl Köller in ophthalmic anesthesia in 188414. Afterwards, the use of the local 
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anesthetic was rapidly disseminated. In the following 
years, it began to be administered in nerve trunk 
injections, as well as in spinal and epidural blocks10. 
Reports describing cocaine toxicity rapidly appeared5 
and included various deaths19. It soon became clear 
that it was necessary to synthesize less toxic drugs. 
A number of agents slowly emerged, e.g. synthetic 
procaine in 1905, tetracaine in 1930, lidocaine in 1944, 
chloroprocaine in 1955, mepivacaine in 1957, prilocaine 
in 1960 and bupivacaine in 1963. The discovery of the 
latter, which is the most frequently used local anesthetic 
to date, was a major step forward in local and regional 
anesthesia because of the quality of anesthesia provided 
and also its duration of action. As expected, descriptions 
of its adverse effects soon began to be reported. In 1979, 
Albright highlighted the severe toxic complications of 
bupivacaine and etidocaine in a seminal editorial of the 
journal Anesthesiology3. Since then, a number of cases 
of refractory cardiac arrest with seizures have been 
notified8. Initially, there were attempts to find agents 
with similar but less toxic characteristics. In 1996, 
ropivacaine emerged, followed by levobupivacaine29 in 
1999. Other authors were dedicated to find an antidote 
for local anesthetic toxicity. In 1998, Weinberg et al. 
demonstrated that lipid emulsions used in parenteral 
nutrition since 1961 were efficient in the combat of 
local anesthetic cardiotoxicity, increasing by 50% the 
mean lethal dose31. Rosenblatt et al. and later Litz et al. 
were the first authors to publish the successful use of 
lipid emulsions in the treatment of cardiac arrest due to 
local anesthetics, when conventional resuscitation had 
failed16,25. Since then, successful cases of lipid emulsion 
use have been reported for management of these 
toxicity reactions9,30. However, before acceptance by the 
medical community, new therapies must always meet 
certain requirements and overcome an initial reluctance 
until scientific and clinical evidence appears to confirm 
therapy efficiency. Lipid therapy in the reversal of local 
anesthetic toxicity, however, seems to be in accordance 
with the recommendations of the medical societies of 
Anesthesiology1,18,23. It is worth mentioning that lipid 
emulsions have also been applied in Anesthesiology 
for a long time. As an example, propofol is a hypnotic 
used in routine practice for more than 25 years and its 
vehicle for solution is a lipid agent21!
Local Anesthetic toxicity
In case of local anesthetic toxicity, the attention 
of the physician should be focused mainly on the 
central nervous system and the cardiovascular system. 
In the brain, inhibiting pathways are the first to be 
suppressed and initially produce patient complaints 
such as a metallic taste in the mouth that may progress 
to seizures as concentrations of the anesthetic rise. 
When the excitatory pathways are also affected, apnea 
and coma occur. With the exception of bupivacaine, 
cardiovascular toxicity becomes evident after plasma 
levels have compromised the central nervous system. 
Cardiovascular toxicity is manifested by arrhythmias 
and refractory myocardial depression, especially when 
the agent used is bupivacaine28. Toxic doses are capable 
of inhibiting sinoatrial and atrioventricular node 
conduction, prolonging the PR space, widening the QRS 
complex, generating atrioventricular blocks of varying 
degrees and arrhythmias, both bradycardias and 
reentrant tachyarrhythmias with ventricular tachycardia 
or fibrillation11. Therapeutic activity and local anesthetic 
toxicity is attributed to Na+ channel block, although 
the flow of K+ and Ca++ is also altered. Bupivacaine 
is bound predominantly to open and inactive Na+ 
channels, which may justify the severity of toxicity. 
Myocardial depression occurs because of several 
factors: inhibition of Ca++ release in the sarcoplasmic 
reticulum by blockade of β-adrenergic receptors, 
decreasing adenylate cyclase activity by reducing the 
synthesis of cyclic adenosine monophosphate and the 
conversion of ADP into ATP28.
Lipid therapy
Until recently, cardiopulmonary bypass was the 
only method known to be effective in the treatment of 
refractory cardiac arrest from local anesthetic overdose17. 
It is easy to imagine the difficulty encountered with this 
methodology in daily practice. Fortunately, nowadays 
the efficiency of lipid therapy in local anesthetic toxicity 
is no longer a questionable debate. The use and interest 
in these solutions, even in toxicity due to a number of 
other drugs have been demonstrated both in animals 
and in humans. Lipid emulsions have already been used 
in the treatment of toxicity due to cyclic antidepressants, 
verapamil, β-blockers, barbiturates among others7. 
Local anesthetics are hydrophobic molecules and 
their lipid solubility is related to potency and toxicity. 
The higher the lipid solubility of the agent, the easier 
it is transported through the cell membrane to reach 
its site of action. Three non-excluding hypothetical 
mechanisms of action of lipid emulsions have been 
proposed. 
The first and most widely accepted mechanism is 
the creation of an expanded plasma lipid phase, into 
which local anesthetic molecules are sequestered. 
Lipophilic local anesthetic molecules are chelated, 
reducing the concentration of the free-base form of 
the local anesthetic, thus making local anesthetics 
unavailable to tissues and resulting in decreased 
toxicity. In the Anglo-Saxon literature this theory is 
termed ‘lipid sink’. This schematic representation is 
based on three facts: the speed of functional recovery 
of the cardiac tissue after the use of lipid emulsion is 
important and consistent with a physical phenomenon. 
Local anesthetics are sequestered in vitro by lipids. 
Sequestration is greater with increasing lipid solubility. 
Finally, in an isolated heart preparation submitted 
to toxic concentrations of local anesthetics, lipids 
accelerate the elimination of these agents4. 
The second mechanism is based upon the 
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concept of inhibition of fatty acid transport at the inner 
mitochondrial membrane, particularly by bupivacaine. 
The hypothesis formulated is that lipid emulsions 
would counteract the reduction in the main source of 
myocardial energy4. 
Finally, the third mechanism originates from 
evidence that lipid emulsions have a positive inotropic 
effect on the isolated heart and may reverse myocardial 
depression due to bupivacaine at lipid levels lower 
than those needed to reduce the aqueous bupivacaine 
concentration26, occurring with increased levels of 
intracellular Ca++. Thus, physiologic, metabolic or 
inotropic pathways may all contribute to antagonize 
local anesthetic toxicity32. 
Various lipid preparations are available in the 
market. With respect to the nature of the lipid source, 
these solutions differ greatly. The most widely used 
preparations are derived from soybean oil with long-
chain triglycerides, soybean oil and coconut oil with 
medium-chain and long-chain triglycerides and those 
incorporating olive oil and fish oil. Each of these 
solutions is of specific interest to parenteral nutrition. 
According to some authors, emulsions based on long-
chained triglycerides were shown to be 2.5 times more 
efficient in the treatment of local anesthetic toxicity20, 
while others consider that their efficiency is equivalent6. 
Preparations that incorporate olive oil and fish oil are 
still less frequently used.
Limitations of lipid therapy
Experimental and clinical studies have 
demonstrated an unquestionable interest in lipid 
emulsions for the treatment of local anesthetic-induced 
toxicity. However, interference with other eventual 
drug treatments in patients must be considered. 
Although lipid emulsions are predicted to be slowly 
infused for nutrition, tolerance to large-dose and bolus 
administration should still be confirmed. Furthermore, 
recent studies have demonstrated that in the event 
of hypoxia lipid emulsions could have deleterious 
effects12 and acidosis could reduce lipid affinity for 
local anesthetics20. This may imply an interest in the 
early administration of these emulsions in cases of toxic 
accidents, before acidosis or hypoxia can limit their 
therapeutic effect.
Guidelines
Lipid emulsions may be infused into peripheral 
veins because these solutions have a low osmolarity 
(between 270 and 345 mOsm/l-1 in 20% solutions). 
In parenteral nutrition, the recommended dose is 0.7 
to 1.3 g of triglycerides/kg-1/day. Triglyceride levels 
should be monitored. The infusion must be reduced 
if levels reach 400 mg/dl-1 and discontinued if levels 
of 1000 mg/dl-1 are obtained2. Despite the respect for 
these recommendations, however, doses have been 
adapted for acute cases of severe local anesthetic 
toxicity. Currently, it seems unreasonable to wait until 
asystole develops to start to administer a bolus of lipid 
emulsion32. In 2007, the Association of Anaesthetists 
of Great Britain and Ireland published the guidelines 
currently accepted for the treatment of local anesthetic 
toxicity. These guidelines were rapidly followed by 
other specialty societies such as the American Society 
of Regional Anesthesia and Pain Medicine23. The 
recommended guidelines are:
1. Secure the airway and maintain oxygenation.
2. Treat seizures with benzodiazepines.
3. Inject a 1.5 ml/kg-1 bolus of 20% lipid emulsion 
over 1 minute.
4. Start an infusion at a rate of 0.25 ml/kg-1/min 
of 20% lipid emulsion.
5. Repeat the bolus twice with 5-minute intervals, 
if adequate circulation is not restored.
6. After five more minutes, increase the infusion 
to 0.50 ml/kg-1/min.
7. Respect the superior dose limit recommended 
for 20% lipid emulsion, which is 10 ml/kg-1 over 30 
minutes.
CONCLUSION
Local and regional anesthetic techniques are 
currently comfortable and safe procedures. However, 
they are not totally devoid of risks, even in capable 
hands. In the past few years, substantial progress has 
been made. Nevertheless, recent estimates still report 
a rate of 7.5 to 20 cases of local anesthetic toxicity 
per 10,000 peripheral blockades performed. Data also 
indicate that four out of 10,000 epidural blocks result 
in systemic local anesthetic toxicity18. Lipid emulsion 
therapy is no longer a matter of controversy because 
its benefit and low risk are evident. Lipid emulsions 
should always be stocked in any setting where patients 
receive large doses of local anesthetics as occurs in 
operating rooms15.  Since surgeons frequently perform 
procedures with large doses of local anesthetics24,27, it 
is wise for them to know these recommendations too. 
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